RU94045926A - PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PRODUCTION AND METHOD OF TREATMENT - Google Patents

PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PRODUCTION AND METHOD OF TREATMENT

Info

Publication number
RU94045926A
RU94045926A RU94045926/14A RU94045926A RU94045926A RU 94045926 A RU94045926 A RU 94045926A RU 94045926/14 A RU94045926/14 A RU 94045926/14A RU 94045926 A RU94045926 A RU 94045926A RU 94045926 A RU94045926 A RU 94045926A
Authority
RU
Russia
Prior art keywords
composition according
acid
secretion
substance
gastric juice
Prior art date
Application number
RU94045926/14A
Other languages
Russian (ru)
Other versions
RU2143899C1 (en
Inventor
Торстен Эк Арне
Эрик Шестранд Свен
Original Assignee
Астра Актиеболаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201297A external-priority patent/SE9201297D0/en
Priority claimed from SE9300029A external-priority patent/SE9300029D0/en
Application filed by Астра Актиеболаг filed Critical Астра Актиеболаг
Priority claimed from PCT/SE1993/000327 external-priority patent/WO1993021920A1/en
Publication of RU94045926A publication Critical patent/RU94045926A/en
Application granted granted Critical
Publication of RU2143899C1 publication Critical patent/RU2143899C1/en

Links

Claims (13)

1. Фармацевтическая композиция, включающая вещество, оказывающее ингибирующее действие на секрецию желудочного сока, увеличивая тем самым величину pH, и кислоторазлагаемое антибактериальное соединение.1. A pharmaceutical composition comprising a substance that has an inhibitory effect on the secretion of gastric juice, thereby increasing the pH value, and an acid degradable antibacterial compound. 2. Композиция по п.1, отличающаяся тем, что веществом, ингибирующим секрецию желудочного сока, является ингибитор протонного насоса. 2. The composition according to claim 1, characterized in that the substance that inhibits the secretion of gastric juice is a proton pump inhibitor. 3. Композиция по п.2, отличающаяся тем, что ингибитором протонного насоса является 5-метокси-2- {[(4-метокси-3,5-диметил-2-пиридинил)-метил]-сульфинил}-1Н-бензимидазол или его фармацевтически приемлемая соль. 3. The composition according to claim 2, characterized in that the proton pump inhibitor is 5-methoxy-2- {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] -sulfinyl} -1H-benzimidazole or its pharmaceutically acceptable salt. 4. Композиция по п.1, эффективная при гастрите и язве желудка, вызванных микробами. 4. The composition according to claim 1, effective in gastritis and gastric ulcer caused by microbes. 5. Композиция по п.1, эффективная при гастрите и язве желудка, вызванных Helicobacter pylori. 5. The composition according to claim 1, effective in gastritis and gastric ulcer caused by Helicobacter pylori. 6. Композиция по п.1, отличающаяся тем, что кислоторазлагаемым антибактериальным соединением является бензилпенициллин. 6. The composition according to claim 1, characterized in that the acid-degradable antibacterial compound is benzylpenicillin. 7. Композиция по п.1, отличающаяся тем, что кислоторазлагаемым антибактериальным соединением является слабоосновной антибиотик. 7. The composition according to claim 1, characterized in that the acid-degradable antibacterial compound is a weakly basic antibiotic. 8. Композиция по п.7, отличающаяся тем, что слабоосновным антибиотиком является слабоосновный эритромицин. 8. The composition according to claim 7, characterized in that the weakly basic antibiotic is weakly basic erythromycin. 9. Композиция по п.7, отличающаяся тем, что антибиотиком является кларитромицин. 9. The composition according to claim 7, characterized in that the antibiotic is clarithromycin. 10. Способ лечения гастрита и язвы желудка, вызываемых Helicobacter pylori, включающий назначение пациенту, страдающему этими заболеваниями, для приема эффективного количества вещества, оказывающего ингибирующее действие на секрецию желудочного сока и повышающего тем самым внутрижелудочную величину pH, вместе с кислоторазрушаемым антибактериальным соединением в количестве, достаточном для лечения названной инфекции. 10. A method of treating gastritis and gastric ulcer caused by Helicobacter pylori, comprising administering to a patient suffering from these diseases, for the administration of an effective amount of a substance that has an inhibitory effect on the secretion of gastric juice and thereby increases the intragastric pH, together with an acid-degradable antibacterial compound in an amount sufficient to treat the named infection. 11. Фармацевтическая композиция, включающая в качестве активных ингредиентов терапевтически эффективное количество вещества, оказывающего ингибирующее действие на секрецию желудочного сока и повышающего тем самым внутрижелудочную величину pH, и терапевтически эффективное количество кислоторазлагаемого антибактериального соединения. 11. A pharmaceutical composition comprising, as active ingredients, a therapeutically effective amount of a substance that inhibits the secretion of gastric juice and thereby increases the intragastric pH, and a therapeutically effective amount of an acid-degradable antibacterial compound. 12. Композиция по п.1 или 11, отличающаяся тем, что в качестве вещества, оказывающего ингибирующее действие на секрецию желудочного сока, она содержит омепразол в количестве от 1 до 200 мг, а кислоторазлагаемое соединение содержится в количестве 250 мг - 10 г. 12. The composition according to claim 1 or 11, characterized in that as a substance that has an inhibitory effect on the secretion of gastric juice, it contains omeprazole in an amount of from 1 to 200 mg, and the acid-degradable compound is contained in an amount of 250 mg - 10 g. 13. Способ получения композиции, охарактеризованной в п.1, отличающийся тем, что вещество, оказывающее действие на секрецию желудочного сока, повышающее внутрижелудочную величину pH, вводят в тот же препарат, что и кислоторазлагаемое антибактериальное соединение. 13. The method of obtaining the composition described in claim 1, characterized in that the substance that has an effect on the secretion of gastric juice, which increases the intragastric pH, is introduced into the same preparation as the acid-degradable antibacterial compound.
RU94045926A 1992-04-24 1993-04-20 Pharmaceutical composition, method of preparation thereof, and treatment method RU2143899C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9201297A SE9201297D0 (en) 1992-04-24 1992-04-24 SYNERGISTIC COMBINATION
SE9201297-0 1992-04-24
SE9300029-7 1993-01-08
SE9300029A SE9300029D0 (en) 1993-01-08 1993-01-08 SYNERGISTIC COMBINATION II
PCT/SE1993/000327 WO1993021920A1 (en) 1992-04-24 1993-04-20 Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic

Publications (2)

Publication Number Publication Date
RU94045926A true RU94045926A (en) 1997-11-27
RU2143899C1 RU2143899C1 (en) 2000-01-10

Family

ID=26661401

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94045926A RU2143899C1 (en) 1992-04-24 1993-04-20 Pharmaceutical composition, method of preparation thereof, and treatment method

Country Status (39)

Country Link
US (3) US5599794A (en)
EP (2) EP0637241B1 (en)
JP (1) JPH07505901A (en)
KR (1) KR100340165B1 (en)
CN (1) CN1041798C (en)
AP (1) AP466A (en)
AT (1) ATE194286T1 (en)
AU (1) AU669903B2 (en)
CA (1) CA2133762C (en)
CZ (1) CZ291201B6 (en)
DE (2) DE637241T1 (en)
DK (1) DK0637241T3 (en)
DZ (1) DZ1683A1 (en)
EE (1) EE03149B1 (en)
ES (1) ES2100135T3 (en)
FI (1) FI944953A (en)
GR (2) GR970300011T1 (en)
HK (1) HK1008296A1 (en)
HR (1) HRP930755B1 (en)
HU (1) HUT71225A (en)
IL (1) IL105155A (en)
IS (1) IS3990A (en)
LV (1) LV12625B (en)
MA (1) MA22878A1 (en)
MY (1) MY121189A (en)
NO (1) NO314288B1 (en)
NZ (1) NZ252759A (en)
PL (1) PL173485B1 (en)
PT (1) PT637241E (en)
RO (1) RO115780B1 (en)
RU (1) RU2143899C1 (en)
SG (1) SG52485A1 (en)
SI (1) SI9300219B (en)
SK (1) SK282420B6 (en)
TN (1) TNSN93040A1 (en)
TW (1) TW276996B (en)
UA (1) UA43830C2 (en)
WO (1) WO1993021920A1 (en)
YU (1) YU49091B (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
SE9500422D0 (en) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
CN1061232C (en) * 1996-04-12 2001-01-31 马理国 Medical composition for gastritis and ulcer
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
ES2232015T3 (en) * 1997-07-25 2005-05-16 Altana Pharma Ag INHIBITOR OF PROTON PUMPS IN THERAPEUTIC COMBINATION WITH ANTIBACTERIAL SUBSTANCES.
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
EP1154771A4 (en) * 1999-02-26 2005-04-20 Nitromed Inc Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
IL151496A0 (en) * 2000-02-29 2003-04-10 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
EP1263445A1 (en) * 2000-03-09 2002-12-11 Ian Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin, metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
SE0002476D0 (en) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SE0103695D0 (en) 2001-11-07 2001-11-07 Thomas Boren A novel non-antibiotic strategy against OGIP infections based on a cereal product
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
MXPA04007169A (en) * 2002-01-25 2004-10-29 Santarus Inc Transmucosal delivery of proton pump inhibitors.
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
WO2004072061A1 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
MXPA06000524A (en) * 2003-07-18 2006-08-11 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders.
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045062A1 (en) * 2003-07-18 2005-10-12 Santarus Inc PHARMACEUTICAL FORMULATIONS TO INHIBIT THE SECRETION OF ACID AND METHODS TO PREPARE AND USE THEM
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10869690B2 (en) * 2017-06-29 2020-12-22 Ethicon Llc Trocar obturator with transverse needle ports
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JP2694361B2 (en) * 1989-02-09 1997-12-24 アストラ アクチエボラグ Antibacterial agent
DK0382489T3 (en) * 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoclonal Anti-Human Papillomavirus Antibody, Hybridoma Cell Producing This, and Method of Preparation thereof
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
ATE209914T1 (en) * 1990-09-14 2001-12-15 Byk Gulden Lomberg Chem Fab USE OF PYRIDYLMETHYLSULFINYL-1H-BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY HELICOBACTER

Similar Documents

Publication Publication Date Title
RU94045926A (en) PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PRODUCTION AND METHOD OF TREATMENT
RU2143899C1 (en) Pharmaceutical composition, method of preparation thereof, and treatment method
RU99128072A (en) NEW S-OMEPRAZOL FORM
RU94027277A (en) PREPARATIONS OF RIZEDRONAT WITH SLOWLY ISOLATION, METHOD OF TREATMENT
US6117868A (en) Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
JPS62502967A (en) Treatment of non-ulcer dyspepsia
CN1207045A (en) Nisin in combination with glycerol monolaurate active against helicobacter
KR100550839B1 (en) Antimicrobials
US4959384A (en) Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
EP1073436A1 (en) IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI)
KR19990023021A (en) New medicinal uses
Harley et al. Treatment of chronic duodenal ulceration: effectiveness of colloidal bismuth subcitrate tablets compared with cimetidine
RU2076708C1 (en) Pharmaceutical composition and method of gastroenteric sickness treatment and prophylaxis
RU2082413C1 (en) Method of duodenum ulcer disease treatment
RU1561262C (en) Composition showing antiinflammatory activity
CA2290549A1 (en) Anti-helicobacter pylori pharmaceutical composition
RU2187310C2 (en) Method of healing ulcer diseases of duodenum
RU2179858C1 (en) Splenotherapy method for treating gastroduodenal ulcers
Calam Future treatment of peptic ulcers
RU2214819C1 (en) Container of medicinal agents for treatment and prophylaxis of gastroenteric diseases caused or mediated by infection with helicobacter pylori
RU97111830A (en) COMPOUNDS FOR INHIBITING GASTRIC ACID SECRET
RU2160104C2 (en) Method and medicinal preparation for treating peptic ulcers
KR0185331B1 (en) Therapeutic agent for gastrointestinal diseases
Lamy et al. Two-Month Assessment of Duodenal Ulcer Healing and Helicobacter pylori Eradication Rates in Patients Treated for One Month with Omeprazole Alone or Combined with Antibiotics
RU2150271C1 (en) Method for treating the cases of chronic prostatitis, gastric and duodenal peptic ulcer